NRX Pharmaceuticals company info

What does NRX Pharmaceuticals do?
NRX Pharmaceuticals (NASDAQ:NRXP) focuses on the development, production, and commercialization of innovative therapeutic products for medical conditions with significant unmet needs. The company is particularly dedicated to advancing treatments for mental health disorders and life-threatening pulmonary diseases. At the forefront of its project portfolio is a treatment aimed at combating severe bipolar depression, showcasing the company's commitment to addressing critical areas of mental health. Another significant endeavor includes developing a breakthrough therapy designed to improve the survival outcomes of patients suffering from pulmonary issues. NRX Pharmaceuticals aims to improve patient care through scientific innovation and strategic partnerships, striving to make a meaningful difference in the lives of individuals facing serious health challenges.
NRX Pharmaceuticals company media
Company Snapshot

Is NRX Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does NRX Pharmaceuticals employ?

people
Employees
18

What sector is NRX Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for NRX Pharmaceuticals?

location pin
Head Office
Wilmington, United States

What year was NRX Pharmaceuticals founded?

founded flag
Year Founded
2015
What does NRX Pharmaceuticals specialise in?
/Pharmaceutical Development /Covid-19 Medicine /Zyesami Treatment /Biotechnological Solutions /Clinical Trials /Respiratory Therapies

What are the products and/or services of NRX Pharmaceuticals?

Overview of NRX Pharmaceuticals offerings
Development of ZYESAMI (aviptadil) for the treatment of severe COVID-19 in patients at risk of respiratory failure, aimed at improving oxygenation and survival.
Advancement of NRX-101, a novel, patented formulation for bipolar depression in patients with acute suicidal ideation or behavior, addressing a significant unmet need in mental health.
Initiation of trials for breakthrough therapies targeting pulmonary diseases, including chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), focusing on innovative treatments.
Collaboration on the development of advanced delivery mechanisms for existing drugs, enhancing efficacy and patient experience through cutting-edge pharmaceutical technology.
Expansion into mental health treatment beyond NRX-101, exploring additional compounds and therapies for a broad range of psychiatric and neurological disorders.
Engagement in strategic partnerships to accelerate the global distribution and accessibility of its pipeline products, particularly in underserved markets.

Who is in the executive team of NRX Pharmaceuticals?

NRX Pharmaceuticals leadership team
  • Dr. Jonathan C. Javitt M.D., M.P.H.
    Dr. Jonathan C. Javitt M.D., M.P.H.
    Co-Founder, Chief Scientist Officer & Chairman
  • Mr. Stephen H. Willard Esq.
    Mr. Stephen H. Willard Esq.
    Acting Corporate Secretary, CEO & Director
  • Dr. Riccardo  Panicucci Ph.D.
    Dr. Riccardo Panicucci Ph.D.
    Chief Technology Officer
  • Dr. Seth L. Van Voorhees Ph.D.
    Dr. Seth L. Van Voorhees Ph.D.
    Treasurer
  • Mr. Richard Clavano Narido
    Mr. Richard Clavano Narido
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Suzanne  Messere
    Suzanne Messere
    Investor Relations
  • Dr. Philip T. Lavin Ph.D.
    Dr. Philip T. Lavin Ph.D.
    Chief Methodologist
  • Dr. Dennis K. McBride Ph.D.
    Dr. Dennis K. McBride Ph.D.
    Chief Strategy Officer & Senior Scientist